Stroke is the second leading cause of "healthy" years lost due to disease (as measured by disability-adjusted life years), and its burden has worsened over time. 1 Globally, the total number of stroke survivors is anticipated to rise to 122.4 million in 2030. 2 Of note, hospital readmissions and increased mortality are common in the years following a stroke. 3, 4 Atherosclerotic cardiovascular disease (ASCVD) is a systemic, progressive disease that affects multiple vascular beds and can lead to vascular events, including stroke. Indeed, patients with a history of previous myocardial infarction (MI), regardless of type, experience increased risk of stroke over time. 5 On the other hand, a history of prior stroke further increases the risk for recurrent coronary heart disease events and MI in post-MI patients. 6 Moreover, in stroke survivors with a history of acute coronary syndrome (ACS), cardiovascular death is the most common subsequent event. 7 In this issue, Zhang et al 8 appraise the impact of history of previous stroke or transient ischemic attack (TIA) on clinical outcomes in patients with ACS. Data are derived from 15 401 patients with ACS from the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry. 9 Prior stroke/TIA was associated with higher rates of 1-year mortality (8.7% vs 3.4%, P < .001) including those patients who underwent percutaneous coronary intervention, reinfarction (5.6% vs 3.8%, P ¼ .015), bleeding (5.2% vs 3.0%, P < .001), and in-hospital bleeding (8.7% vs 5.8%, P < .001). The impact of different antithrombotic therapies or dual antiplatelet therapy on clinical outcomes was similar.
Patients with a history of stroke are more commonly older and more likely to have comorbidities such as hypertension, diabetes, or atrial fibrillation. 10 The study by Zhang et al 8 provides useful information corroborating that patients with ACS with a history of stroke/TIA are of older age and at "very high" risk due to the presence of additional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and concurrent diseases (congestive heart failure, kidney function impairment, lower levels of hemoglobin, malignancies) and a higher burden of atherosclerotic disease (MI, peripheral artery disease). On the other hand, they appear to receive less intensive medical and invasive therapy.
Patients with a prior stroke/TIA may represent a group of increased risk of intracranial bleeding following the intensified antithrombotic therapy when experiencing an ACS. 11 In the PLATelet inhibition and patient Outcomes trial, despite optimal medical and invasive therapy, mortality was doubled and rates of stroke and intracranial hemorrhage increased by 3 and 4 times, respectively. 12 In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38, prasugrel adversely affected patients with a history of stroke/TIA. 13 In the setting of ACS, the preferential use of clopidogrel within 1 year from stroke/TIA onset and ticagrelor thereafter is a reasonable suggestion. 11 However, there is a need to develop and appraise specific strategies to optimize management of this group of patients.
All in all, this investigator-initiated retrospective international registry 8 adds to the limited knowledge regarding optimal management of patients with ACS with a history of stroke/ TIA. In general, this group of patients comprises an aging population who, despite evidence of a more extensive atherosclerotic disease, coexisting ASCVD. and other comorbidities and risk factors, may not be treated optimally for secondary prevention. Indeed, lower rate prescription of b-blockers and statins is reported by Zhang et al. 8 According to current guidelines for lipid management, low-density lipoprotein cholesterol should be targeted to achieve levels lower than 55 mg/dL (1.4 mmol/L) or even to a lower threshold (40 mg/dL, 1.0 mmol/L). 14 Antithrombotic (antiplatelet and/or anticoagulant) treatment should also be tailored as indicated. Finally, taking into account that patients with prior stroke/TIA were understudied in previous randomized clinical trials, there is a need for further investigation to develop and evaluate safe and effective treatment strategies.
